Advantage of Tolerability following Arsenic Trioxide-VTD vs VRD in newly diagnosed multiple myeloma patients: a prospective, open-label study
International Journal of Medical Sciences · 2025
DOI: 10.7150/ijms.110231 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift International Journal of Medical Sciences, 2025. Verfasst von Xinyu Zuo und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Huadong Hospital, Fudan University, Shanghai, China. Hauptthemen laut MEDLINE: Multiple Myeloma, Arsenic Trioxide, Antineoplastic Combined Chemotherapy Protocols. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Hematology, Huadong Hospital, Fudan University, Shanghai, China.
- Department of Hematology, The First Affiliated Hospital of Fujian Medical University, Fuzhou, China.
Zitieren
APA
Zuo, X., Yang, A., Chen, P., Xie, Y., Zeng, Z., & Ma, J. (2025). Advantage of Tolerability following Arsenic Trioxide-VTD vs VRD in newly diagnosed multiple myeloma patients: a prospective, open-label study. International Journal of Medical Sciences. https://doi.org/10.7150/ijms.110231
Vancouver
Zuo X, Yang A, Chen P, Xie Y, Zeng Z, Ma J. Advantage of Tolerability following Arsenic Trioxide-VTD vs VRD in newly diagnosed multiple myeloma patients: a prospective, open-label study. International Journal of Medical Sciences. 2025. doi:10.7150/ijms.110231
BibTeX
@article{Zuo2025,
author = {Zuo, Xinyu and Yang, Apeng and Chen, Pingping and Xie, Yanhui and Zeng, Zhiyong and Ma, Jiexian},
title = {Advantage of Tolerability following Arsenic Trioxide-VTD vs VRD in newly diagnosed multiple myeloma patients: a prospective, open-label study},
journal = {International Journal of Medical Sciences},
year = {2025},
doi = {10.7150/ijms.110231}
}
EUVIMED